PARIS–(BUSINESS WIRE)–Regulatory News: “Plan de Relance pour l’industrie – Secteurs Stratégiques” Post this CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today reports its annual results […]

The funds raised represent 110% of the Initial Offer; the net amount of €14.9 million will contribute to the Company’s short-term financing Together, demand and underwriting and guarantee commitments reached €18.8 million and were allocated as follows: €9.2 million as part of the global offering, including €7.8 million in subscription […]

PARIS–(BUSINESS WIRE)–Regulatory News: “This agreement in principle with the EIB on new repayment terms for the loan is a positive signal for the Company. ” Post this CARMAT (FR0010907956, ALCAR, eligible for PEA-PME equity saving plans), designer and developer of the world’s most advanced total artificial heart, aiming to provide […]

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aimed at providing a therapeutic alternative for patients suffering from advanced biventricular heart failure (the “Company” or “CARMAT“), today announced the completion of a capital increase for a total amount of €7 million, subscribed in its […]

ARIS–(BUSINESS WIRE)–Regulatory News: “During the first half of 2023, the production ramp-up we were anticipating was significantly disrupted by supply issues. Due to the lack of a sufficient number of devices, we were late in generating the demand from hospitals, hence limited revenues in the first half of the year. […]

The company confirms its sales target of €10-13 million for 2023 PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, informs its shareholders that the Combined General […]

Gradual resumption in Aeson® implantations in line with progressive production ramp-up over the year 2023 Cash position of €51 million as of December 31, 2022 and active exploration of financing options to extend cash runway beyond July 2023 Confirmation of a sales target of €10 to €13 million in 2023 CARMAT […]

PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced the co-option of Alexandre Conroy to the Company’s Board of Directors in place of Jean-Pierre Garnier, […]